Preliminary data indicate the presence of inflammatory derangements in AML, necessitating a comprehensive examination of inflammatory effector cytokines involved in AML pathogenesis and therapeutic responses. Addressing this issue requires overcoming two major challenges: the existence of over 300 cytokines associated with human disease, and the presence of functional yet low-level cytokines. A high-throughput method capable of characterizing numerous cytokines and identifying potential therapeutic targets is essential, along with a cytokine profiler that captures a wide dynamic level range. We propose utilizing NULISA, a novel method that enables the comprehensive characterization of more than 200 important cytokines and chemokines with ultra-high sensitivity and scalable multiplexing, effectively tackling both challenges. 88 Serum samples from AML and healthy subjects were profiled using Alamar’s NULISAseq 200-plex Inflammation panel. Unsupervised clustering showed different sample groups clustering together and differential expression analysis revealed unique inflammation profiles for AML patients compared to healthy donors. These results revealed that 200-plex Inflammation panel can detect various circulatory inflammatory biomarkers with high sensitivity and specificity and these features can reveal novel biological insights into inflammatory derangements in AML disease.
CSO
Dr. Willams serves as the company’s Chief Scientific Officer. He was previously Chief Medical Officer at Standard Biotools and at SomaLogic where he pioneered the discipline for discovery and validation of predictive, diagnostic and prognostic models using machine-learning applied to large-plex proteomics. 20 such tests were used for drug characterization, safety and efficacy when incorporated in clinical drug trials at Pharma/Biotech and 17 different multivariate tests were validated and translated into regulated healthcare uses. Prior to SomaLogic, Dr. Williams was at Pfizer in the UK and the USA as a clinical triallist in Translational Medicine, and subsequently as VP, Global Clinical Technology. He sat on the National Advisory Council for the National Institute of Biomedical Imaging and Bioengineering, the Executive Committee for the FNIH Biomarkers Consortium, and worked with FDA and PhRMA on developing evidentiary standards for biomarker qualification. Dr. William’s medical training was in London, at Charing Cross and Westminster Medical School, followed by a PhD in medicine/physiology at the same institution and training in Radiology at the University of Newcastle Upon Tyne. Steve is co-inventor on 26 proteomics patents and author/coauthor on multiple foundational proteomics manuscripts.
CFO
Mr. McAnear serves as the company’s Chief Financial Officer. He brings over 25 years of operational and financial leadership experience across various sectors and was instrumental in taking 10x Genomics public in 2019, serving as its CFO for over five years. Mr. McAnear served for over 3 years as Tesla’s VP of Worldwide Finance and Operations, supporting landmark initiatives such as the Model X and Model 3 launches and Solar City acquisition. He also held various roles at Apple and J&J earlier in his career and served as a naval officer and aviator for over 9 years.